Literature DB >> 20089977

Clostridium difficile--beyond antibiotics.

Lorraine Kyne.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089977     DOI: 10.1056/NEJMe0910055

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

Review 1.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

2.  Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT).

Authors:  Panagiotis Papatheodorou; Jan E Carette; George W Bell; Carsten Schwan; Gregor Guttenberg; Thijn R Brummelkamp; Klaus Aktories
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

3.  Bezlotoxumab.

Authors:  Danial E Baker
Journal:  Hosp Pharm       Date:  2017-03

Review 4.  Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Authors:  Ardeshir Rineh; Michael J Kelso; Fatma Vatansever; George P Tegos; Michael R Hamblin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01       Impact factor: 5.091

5.  Antimicrobial photodynamic therapy in the colon: delivering a light punch to the guts?

Authors:  Mark Wainwright; Tianhong Dai; Michael R Hamblin
Journal:  Photochem Photobiol       Date:  2011-04-12       Impact factor: 3.421

6.  Interaction of the Clostridium difficile Binary Toxin CDT and Its Host Cell Receptor, Lipolysis-stimulated Lipoprotein Receptor (LSR).

Authors:  Sarah Hemmasi; Bernd A Czulkies; Björn Schorch; Antonia Veit; Klaus Aktories; Panagiotis Papatheodorou
Journal:  J Biol Chem       Date:  2015-04-16       Impact factor: 5.157

7.  Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.

Authors:  Kasper Krogh Andersen; Nika M Strokappe; Anna Hultberg; Kai Truusalu; Imbi Smidt; Raik-Hiio Mikelsaar; Marika Mikelsaar; Theo Verrips; Lennart Hammarström; Harold Marcotte
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

8.  Intracolonic vancomycin for severe Clostridium difficile colitis.

Authors:  Peter K Kim; Heesun C Huh; Hillel W Cohen; Elyssa J Feinberg; Salman Ahmad; Christina Coyle; Sheldon Teperman; Hugh Boothe
Journal:  Surg Infect (Larchmt)       Date:  2013-04-05       Impact factor: 2.150

Review 9.  Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.

Authors:  Greg Hussack; Jamshid Tanha
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

10.  Clostridium difficile: moving beyond antimicrobial therapy.

Authors:  Amesh A Adalja; John A Kellum
Journal:  Crit Care       Date:  2010-09-16       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.